Johnson & Johnson's (JNJ.US) oral IL-23R antagonist achieved positive top-line results in two Phase III studies
Generated by AI AgentMarket Intel
Tuesday, Nov 19, 2024 3:50 am ET1min read
JCI--
On November 18, Johnson & Johnson (JNJ.US) announced positive key results from its Phase III ICONIC-LEAD study of Icotrokinra (JNJ-2113), an oral IL-23R antagonist, in the treatment of plaque psoriasis (PsO). This is the first oral IL-23R-targeted drug to successfully complete a Phase III study.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet